Deals channel feed – Endpoints News

Deals channel feed

Revolution and Iambic to combine data and AI models in R&D deal for cancer drugs

4 hours ago

Updated: Merck drops $10B for respiratory drugmaker Verona Pharma in its first acquisition of 2025

5 hours ago

Quanterix closes Akoya deal after competing bid

Yesterday

Shell company Concentra has found its rhythm, with Cargo Therapeutics as its latest buyout target

Yesterday

Roche-backed Chugai taps into longevity field with Pfizer-allied Gero

2 days ago

Sage talked to 43 'counterparties' before inking Supernus deal

6 days ago

Shionogi, BioVersys team up on antibiotics for lung disease in deal worth up to $614M

Last week

Kevin Tang's Concentra snags another buyout, this time for IGM Biosciences

Last week

Unnatural Products taps argenx's help for ringed molecules, expands internal work into obesity

Last week

Sage plans to lay off almost every employee after inking Supernus deal

Last week

AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal

Last week

Alphabet’s Calico inks $25M licensing deal for Mabwell’s IL-11 programs

Last week

A dinner in Paris revived talks for Sanofi's $9.5B deal for Blueprint

Last week

Vor Bio bounces back with autoimmune drug pact, $175M private placement

Last week

Novartis strikes cardiovascular discovery deal with Flagship’s ProFound

Last week

Revolution inks up to $2B 'flexible' funding deal to advance RAS inhibitor pipeline

3 weeks ago

Illumina to buy SomaLogic for $350M upfront, pushing further into proteomics

3 weeks ago

Humana details plans to grow its primary care business as competing clinics shutter

3 weeks ago

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

4 weeks ago

NextCure inks ADC deal with Shanghai drugmaker

4 weeks ago

Updated: Sage's roller coaster ends in $561M acquisition by Supernus

4 weeks ago

Former CEO Anne Wojcicki wins bid for 23andMe

4 weeks ago

CureVac CEO on BioNTech deal: Come together 'rather than fighting each other in court'

4 weeks ago

BioNTech to acquire CureVac in all-stock deal valued at $1.25B

4 weeks ago

12 3 4 Next page Last page